Logo

Serologicals to Acquire Ion Channel Cell Line Provider Cytomyx

Mar 14, 2006

NEW YORK, March 14 (GenomeWeb News) - Serologicals will acquire Cytomyx, a wholly owned subsidiary of Cytomyx Holdings, Serologicals said today.

 

"Through this acquisition, our drug-discovery business will expand their service offerings to include GPCRs, kinases, and ion channels, the top three most-important target classes today," said Serologicals president and CEO, David Dodd in a statement.

 

Cytomyx has 23 ion channel cell lines commercially available and more in its pipeline, said Serologicals.

 

Serologicals expects to complete the acquisition in the first quarter of 2006 and for the acquisition to be "slightly accretive" in fiscal year 2006.

 

Financial details were not provided.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.